Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422982 | 0.88 | ALDH1A1 (0.57) | CYP2C9CYP2C19MAPK14HTR2BALDH1A1 | |
| SCHEMBL1593832 | 0.88 | ALDH1A1 (0.57) | CYP2C9CYP2C19MAPK14HTR2BALDH1A1 | |
| SCHEMBL19396258 | 0.87 | CYP2C9 (0.51) | CYP2C9CYP2C19MAPK14HTR2BALDH1A1 | |
| SCHEMBL1594529 | 0.86 | ALDH1A1 (0.55) | CYP2C9ALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL1594066 | 0.85 | ALDH1A1 (0.61) | MAPK14ALDH1A1PKMPOLBGAA | |
| SCHEMBL1594280 | 0.84 | ALDH1A1 (0.60) | MAPK14ALDH1A1POLBGAAHDAC4 | |
| SCHEMBL1595811 | 0.84 | ALDH1A1 (0.60) | MAPK14ALDH1A1POLBGAAHDAC4 | |
| SCHEMBL1594739 | 0.84 | ALDH1A1 (0.68) | ALDH1A1POLBGAAHDAC4SMN1; SMN2 | |
| SCHEMBL1594170 | 0.83 | ALDH1A1 (0.59) | MAPK14ALDH1A1POLBGAAHDAC4 | |
| SCHEMBL1594219 | 0.83 | ALDH1A1 (0.59) | MAPK14ALDH1A1POLBGAAHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273968-A1 | MAO-B INHIBITORS AND REHABILITATION | DART NEUROSCIENCE, LLC | 2017-09-28 | — | — | US | disclosed |
| EP-2465850-B1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2016-11-23 | — | — | EP | disclosed |
| WO-2016044635-A1 | MAO-B INHIBITORS AND REHABILITATION | DART NEUROSCIENCE, LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| US-8791137-B2 | Therapeutic compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-07-29 | — | — | US | disclosed |
| EP-1989185-B1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-8399487-B2 | Pyrazole compounds and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-03-19 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | disclosed |
| WO-2007100851-A1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | MAOB, MAOA, HTR1B | CYP2C9 158/4885CYP2C19 53/4885MAPK14 3800/4885 |
| US-20170273968-A1 | MAO-B INHIBITORS AND REHABILITATION | MAOB, MAOA, HTR2B | CYP2C9 587/4885CYP2C19 194/4885MAPK14 1743/4885 |
| US-20070203154-A1 | Therapeutic Compounds | MAOB, MAOA, HTR1B | CYP2C9 158/4885CYP2C19 53/4885MAPK14 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.